Journal of Clinical & Experimental Pharmacology

Diagnostic validity comparison between criteria based on cerebrospinal fluid Alzheimerâ??s disease biomarkers

3^rd World Congress on Pharmacology

August 08-10, 2016 Birmingham, UK

J Antonio Monge Argiles

University General Hospital, Spain

Posters & Accepted Abstracts: Clin Exp Pharmacol

Abstract:

Early identification of patients with Alzheimer�??s disease (AD) has become a priority within the neurosciences. To this end, the National Institute on Aging and the Alzheimer�??s Association (NIA-AA) criteria for the diagnosis of preclinical and prodromal AD (or mild cognitive impairment [MCI] due to AD) has recently been defined. In these criteria, cerebrospinal fluid (CSF) biomarkers have been accepted as evidence of the underlying pathophysiology of the disease, especially for research, but their use is yet limited in daily clinical practice. The standardization of the use of biomarkers is still limited, the results between laboratories are variable and there is no consensus of how exactly they should be used. Subsequently, different criteria for assessing the CSF biomarkers of AD have been published. These studies propose the use of only some of the biomarkers in isolation, such that relevant information would be lost, or complex mathematical formulas needed that in our view, would hinder their use. We propose a simple measurement of these biomarkers that comprises considering them clearly altered when three or more abnormal variables are obtained, where we included Aβ, t-tau, p-tau and Aβ/tau ratios as well. In this way, we lose information concerning the disease process, while confirming that this process is occurring in both pathways of the illness, amiloyd and neuronal injury, and with no need to perform complex mathematical calculations. We suggest that the criteria proposed herein are more sensitive than the NIA-AA criteria for diagnosing MCI due to AD because, by using the ratios the relationship between the two pathophysiological pathways of the disease is included in its assessment.

Biography :

Email: monge_jos@gva.es